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IL-4 and INFy are multifunctional lymphokines with profound effects on the
immune response. In some cases they display similar effects, such as increasing T
cell-mediated cytotoxicity (1), while in other situations, such as the regulation of
Ig isotype expression, antagonistic effects have been demonstrated (2).
Recent studies in mice clearly indicate that the in vivo synthesis ofIgE is highly
dependent upon the balance between the production ofIL-4 and IFN-,y. Adminis-
tration of anti-IL-4 neutralizing antibody blocks the primary, the secondary, and
most ofthe ongoing IgE responses (3), whereas the injection of anti-IFN-y neu-
tralizing antibodyhasthe reverseeffect (4). Thereisstrong evidence that the isotype
selection is dictated by the selective activation ofeither Thl or Th2 CD4+ T cell
subsets. Indeed, Th2 cells were shown to produce IL-4 and IL-5, but not IFN-,y,
whereasThl cellsproduceIL-2, IFN-y, andlymphotoxin, butnotIL-4(5). Inhumans,
this dichotomy of Th cells is not as apparent, since the majority of T cell clones
producingIL-4 also secrete IFN-y and IL-2 (6). However, several studies have indi-
cated that the in vitro synthesis of human IgE requires the presence of IL-4 and
that it is suppressed by IFN-y (7, 8). This suggests that, like in the murine model,
human IgE synthesis is also dependent upon the balance between IL-4 and IFN-'y.
We demonstrateherethat IL-4 suppresses the invitro production ofIFN-y byhuman
PBMC and that there is a parallelism between this suppression and the IgE syn-
thesis by allogeneic stimulated PBMC. Hence, in addition to triggeringcellular in-
teractions leading to IgE synthesis, IL-4 also blocks the synthesis ofa strong inhib-
itor of the IgE response.
Volume 170 November 1989 1751-1756
Materials and Methods
BriefDefinitive Report
Reagents.
￿
PHA was obtained from Wellcome Diagnostics (Beckenham, UK) and PWM
was fromGibco Laboratories (Grand Island, NY). HumanrIL-4was purchased from Gen-
zyme(Boston, MA). Cycloheximide wasobtainedfromSigmaChemical Co. (St. Louis, MO).
Neutralizing anti-IL-4 mAb (IgG1, u) hybridoma culture supernatants were a kind gift
from Dr. C. Heuser (CIBA-GEIGY, Switzerland).
Cell Preparation and Culture Conditions.
￿
Mononuclear cells were isolated from heparinized
venous blood ofhealthy volunteers by centrifugation over a Sepracell gradient (Sepratech
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Co., Oklahoma City, OK). Cells were cultured in HB101 culture medium (Hana Biologics
Inc., Alemeda, CA) supplemented with penicillin G (100 U/ml), streptomycin (100 fag/ml)
(Sigma Chemical CO.), L-glutamine (2 mM/liter) (Gibco Laboratories), sodium pyruvate (10
mM/liter), and Hepes (10 mM/liter).
PBMC (1 .5 x 106 in 1 ml) were cultured in 48-well culture plates (Costar, Cambridge,
MA) in a humidified atmosphere of 5% C02 and 95% air. Culture supernatants from
mitogen-stimulated cells (PHA 1% ; PWM 1% ; vol/vol) were harvested after 3 d. Two-way
mixed lymphocyte cultures (MLC), containing equal numbers ofPBMC from two unrelated
donors, were harvested after 6 d, except when otherwise indicated.
RIAs.
￿
The IFN-,y levels in cell-free culture supernatants were detected by a commer-
cially available solid-phase RIA kit (Centocor Co., Malvern, PA). IgE was measured by a
solid-phase RIA using two mAbs, exactly as previously described (9). The net synthesis of
IgE and ofIFN-,y was determined by substracting the values measured in the culture super-
natants of cycloheximide-treated cells from those of untreated cells.
Northern Blot Analysis.
￿
Total cytoplasmic RNA was purified from 107 MLR mononuclear
cellsby this guanidine-thiocyanate method (10) and subjected to electrophoresis on a form-
aldehyde-denaturing agarose gel. After transfer to a nitrocellulose membrane (Schleicher &
Schuell, Inc,, Keene, NH), the samples were hybridized (11) with a 1.4-Kb nick-translated
Barn HI/Bam HI fragment ofthe human IFN-,y cDNA sequence derived from pSVT69 (12).
After autoradiography, the IFN-,y probe was washed offand the membrane was rehybridized
with a human y-actin cDNA probe.
Results
In the course of our studies on the regulation of IgE synthesis by PBMC from
healthy adults, we noticed that IL-4 not only triggered the synthesis of IgE but also
suppressed the production of IFN-y by these cells. In 21 consecutive experiments
where the levels of IFN-y in the unstimulated cultures ranged from 5 to 45 U/ml,
IL-4 induced a suppression ranging from 70 to 100%. These observations prompted
us to examine the effect of IL-4 on the synthesis of IFN-,y by PBMC stimulated
with mitogens or with allogeneic cells. The data in Tables I and II clearly indicate
that IL-4 strongly suppressed the production of IFN-y induced by optimal concen-
Efect of IL-4 on the Spontaneous and Mitogen-induced IFN-y Production
TABLE I
Shown are the mean values of four replicate cultures; the coefficient ofvariation
was <20% . The isotype-specific control mAb anti-Lol P1,IgGl,x (8) does not
alter the IL-4 effect.
Added to cultures Exp. 1
IFN-,y
Exp. 2
U/ml
Exp. 3
7 20 34
IL-4 1 3 5
PWM 370 530 2,700
PWM + IL-4 80 250 480
PWM + IL-4 + anti-IL-4 mAb 470 450 ND
PWM + IL-4 + anti-Lot PI mAb 75 260 ND
PHA 1,000 1,680 1,500
PHA + IL-4 300 430 380
PHA + IL-4 + anti-IL-4 mAb 1,100 1,490 ND
PHA + IL-4 + anti-Lol PI mAb 360 425 NDPELEMAN ET AL .
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TABLE II
Elect of IL-4 on IFN-y Production during MLC
Shown are themean values offour replicate cultures ; the coefficient ofvariation
was <20% . The isotype-specific control mAb anti-Lol P1,IgGl,ic (8) does not
alter the IL-4 effect .
trations of PWM, PHA, or by allogeneic cells. This effect was blocked by a neu-
tralizingmAb to IL-4 . In all these experiments, IL-4 was used at a concentration
of300 U/ml, which is optimal forthe induction ofIgE synthesis . However, the IL-4-
induced suppression ofIFN-.y is dose dependent . In the representative experiment
shown in Fig. 1, increasing concentrations of IL-4 were added to aMLC. As seen,
IL-4 had a reciprocal and dose-dependent effect on the synthesis ofboth IFN-T and
IgE . The IgE levels were low due to the short duration (6 d) of the culture. As an-
otherapproach to analyze themechanism ofIFN-y suppressionby IL-4, time course
experiments were performed . As shown in Fig. 2, IL-4 must be present from the
very beginning oftheMLC in order to exertmaximal suppressionofIFN-'Y produc-
tionandto induce IgE synthesis . It is of note that neither IL-1, IL-2, IL-6, norTNFcl,
tested overa wide concentration range, could inhibit the IFN-7 production by allo-
geneic stimulated PBMC (data not shown) .
Finally, we have demonstrated that IL-4 inhibits the expression of IFN-'ymRNA
in allogeneic stimulated cells . In theexperiment shownin Fig . 3, cellswere analyzed
by Northern blot hybridization forthe expression ofIFN-TmRNA aftera 3 d stim-
ulation in MLC, in the presence (lane 1) or absence (lane 2) of 300 U/ml of IL-4 .
FIGURE 1 .
￿
Dose-dependent effect of IL-4 on
the synthesis of IFN-y andIgEduringMLC.
MLCwas performed asdescribed inMaterials
andMethods . IL-4, at the indicated concen-
trations, wasadded at the start ofthe cultures .
Culture supernatant was harvested after 6 d .
Added to MLC Exp . 1
IFN-'y
Exp . 2
U/ml
Exp. 3
- 124 184 120
IL-4 30 36 8
IL-4 + anti-IL-4 mAb 96 139 ND
IL-4 + anti-Lol P1 mAb 28 36 ND1754
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FIGURE 2 . Time-dependent
IL-4 effect on the synthesis of
IFN-y and IgE during MLC.
IL-4 (300 U/ml) was added to
MLC at the indicated time-
points .The levels ofIFN-yand
of IgE were determined after a
12-d culture period .
FIGURE 3 .
￿
Effect of IL-4 on IFN-y mRNA . (A) Ethidium bro-
mide staining of the 18 S and 28 S ribosomal RNA bands from
the equalizedRNA samples used to prepare the RNAblot . (B)
Northern blot analysis of IFN-ymRNA in the presence (lane 1)
or absence (lane 2) of IL-4 (300 U/ml) . The data shown are
respresentative of four separate experiments .
After normalization according to the human -y-actinmRNA level, whichwas not in-
fluenced by IL-4 treatment, the accumulative IFN-ymRNA leveldisplayed an inhi-
bition of 75% (as determined by densitometer scanning) in the presence of300 U/ml
IL-4 (data not shown) .
Discussion
Ourobservations demonstratethat IL-4 inhibits the in vitro production of IFN-'r
byhumanPBMC . The suppression is observed both at the proteinand at themRNA
level; it is dose and time dependent, and it is blocked by a neutralizingmAbto IL-4 .
The dose-response and the kinetic studies confirm the prevalent concept of an in-
verse relationship between the production of IgE and of IFN-y.
The datafrom thetime course experiments may further suggest that the selection
of the IgE isotype expression occurs early in the course of an immune response .
Indeed, IL-4 has to be present at the initiation ofthe lymphocyte activation in order
to exert its maximal suppressive effect on the production of IFN-y, indicating that,PELEMAN ET AL.
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whenlymphocytes are activated in such away thatIL-4 isproduced first, this would
prevent the subsequent production ofIFN-y. Therefore, the balance between these
two antagonistic lymphokines may be significantly influenced by the chronological
order of activation oftheir respective gene.
We are currentlyinvestigating the molecular mechanism ofthese observations and
we are testing whether the IL-4-induced inhibition ofthe accumulation of IFN-y-
specific mRNA in allogeneic stimulated cells is due to a reduced transcription rate
or to an increased mRNA degradation.
The observed effect ofIL-4 cannot be attributed to inhibition ofthe lymphocyte
activation, sincethe addition ofIL-4 tocells stimulated bymitogens orby allogeneic
cells enhanced the DNA synthesis, as measured by [3H]thymidine uptake (data not
shown).
IL-2 has been reported to increase the production ofIFN-'r by T cells stimulated
withmitogensorantigen(13). We observed that IL-4 stillsuppressed theIFN-yproduc-
tion in MLRcultures supplemented with IL-2 (datanot shown). This indicates that
the IL-4 effect is not due to the inhibition ofthe IL-2-mediated IFN-'r induction.
The suppressive activity of IL-4 on the production ofIFN-y might occur in vivo
aswell. Indeed, in a recent study on murine Leishmaniasis, Heinzel et al. (14) reported
that susceptible strains ofmice (BALB/c) express high tissue levels ofIL-4 mRNA
and lowlevels ofIFN-y mRNA, whereasthe resistantC57BL/6 strain expresses high
levels ofIFN-'Y and low levels ofIL-4. As expected, BALB/c mice display a strong
IgE response after Leishmania infection, whereasC57BL/6do not. IFN-ywasshown
toplay acritical roleinthe resistance tothis parasite (15, 16). Relevant to thepresent
data is the observation that treatment of susceptible mice with anti-IL-4 mAb sig-
nificantly enhanced their resistance to the parasite. As suggested by the authors,
this might be dueto the neutralization oftheharmful effects ofIL-4 in this infection
or to the restoration ofIFN-y production. The latter possibility is supportedbythe
present observations that IL-4 suppresses the production of IFN-y.
Since IFN-y plays a key role in protective immunity against several pathogens
withan obligatoryorfacultativeintracellular cycle, the observationthat IFN-yproduc-
tion is suppressed by IL-4 may berelevant inclinical conditions where an increased
IgE production (as amarker ofhigh IL-4 and low IFN-y production) is associated
with either chronic parasitic disease or increased susceptibility to infections.
Summary
rIL-4 inhibits the production of IFN-y by PBMC stimulated with mitogens or
allogeneic cells. The suppression is observed at the protein and at the mRNA level;
it is dose and time dependent, and it is abolished by a neutralizing mAb to IL-4.
It is suggested that the balance between the production of IL-4 and IFN-'r may be
significantly influenced bythechronological orderofactivation oftheirrespective gene.
Receivedfor publication 6june 1989.
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